Powered by

Powered by Portfolio Grader

Ligand Pharm (LGND)

109.00 1.05 (0.95%) 7:22 EST
LGND Stock Quote Delayed 15 Minutes

  • LGND Stock Chart

  • Historical LGND Prices

  
Dividend & Yield:       N/A (N/A)
P/E:       50.93
Market Cap:       2.32B
EPS:       2.14
Volume:       2,081
Day's Range:       98.56 - 131.00
52wk Range:       98.56 - 278.62
Quotes delayed at least 20 mins.
Historical Data for LGND
Month:  Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Year:  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Range:  1 Month 3 Month 1 Year
Date Open High Low Volume Close Change %
01/16/19 130.50 131.00 98.56 8,569,517 110.05 -21.72   -16.48%
01/15/19 128.11 132.74 127.20 574,053 131.77 3.40   2.65%
01/14/19 133.70 133.70 126.76 994,579 128.37 -6.32   -4.69%
01/11/19 135.65 137.38 132.85 411,300 134.69 -1.28   -0.94%
01/10/19 140.91 140.91 129.46 904,840 135.97 -6.04   -4.25%
01/09/19 140.93 144.95 140.00 510,302 142.01 1.66   1.18%
01/08/19 143.72 144.71 139.53 410,102 140.35 -2.12   -1.49%
01/07/19 138.61 142.94 137.54 529,568 142.47 4.72   3.43%
01/04/19 134.94 140.74 134.94 407,100 137.75 5.11   3.85%
01/03/19 137.43 138.20 132.49 421,667 132.64 -4.36   -3.18%
01/02/19 133.59 138.05 132.85 384,310 137.00 1.30   0.96%
12/31/18 136.29 139.00 134.31 466,300 135.70 -0.14   -0.10%
12/28/18 137.20 140.00 135.01 378,100 135.84 -1.05   -0.77%
12/27/18 135.80 139.24 131.35 467,723 136.89 -0.97   -0.70%
12/26/18 128.70 138.28 128.70 469,009 137.86 9.50   7.40%
12/24/18 132.14 135.61 128.20 235,900 128.36 -4.14   -3.12%
12/21/18 136.35 138.79 132.05 1,183,400 132.50 -3.45   -2.54%
12/20/18 132.60 138.70 132.60 820,624 135.95 3.16   2.38%
12/19/18 135.21 144.50 130.51 743,868 132.79 -0.77   -0.58%
12/18/18 134.78 134.78 131.23 483,311 133.56 1.09   0.82%
12/17/18 136.61 141.01 131.33 725,839 132.47 -4.39   -3.21%
12/14/18 140.68 143.14 135.55 808,000 136.86 -4.92   -3.47%
12/13/18 149.05 149.05 141.10 492,736 141.78 -6.15   -4.16%
12/12/18 147.97 151.86 146.59 355,456 147.93 1.36   0.93%
12/11/18 151.08 154.25 145.24 373,515 146.57 -2.05   -1.38%
12/10/18 146.44 150.67 144.30 493,261 148.62 3.01   2.07%
12/07/18 152.55 154.37 143.95 447,600 145.61 -7.97   -5.19%
12/06/18 150.66 153.80 147.51 579,807 153.58 0.81   0.53%
12/04/18 162.70 162.95 151.51 585,200 152.77 -9.39   -5.79%
12/03/18 160.13 163.94 158.28 448,629 162.16 4.39   2.78%
11/30/18 165.06 166.52 156.40 668,600 157.77 -6.85   -4.16%
11/29/18 161.30 165.89 159.81 391,231 164.62 1.95   1.20%
11/28/18 155.68 165.08 154.44 503,432 162.67 7.28   4.68%
11/27/18 154.69 159.39 152.38 594,708 155.39 -0.34   -0.22%
11/26/18 152.03 157.46 150.48 403,214 155.73 5.93   3.96%
11/23/18 149.63 155.51 149.60 154,000 149.80 -1.68   -1.11%
11/21/18 0.00 151.48 151.48 0 151.48 2.62   1.76%
11/20/18 146.07 153.99 144.14 575,485 148.86 0.32   0.22%
11/19/18 153.85 154.24 147.56 479,926 148.54 -5.92   -3.83%
11/16/18 150.72 156.46 145.51 510,700 154.46 2.55   1.68%
11/15/18 147.47 153.20 145.59 459,704 151.91 4.11   2.78%
11/14/18 149.87 151.40 143.24 662,855 147.80 -0.63   -0.42%
11/13/18 155.65 158.08 147.11 695,056 148.43 -7.04   -4.53%
11/12/18 157.38 160.35 154.25 646,034 155.47 -3.12   -1.97%
11/09/18 168.12 169.21 156.04 824,500 158.59 -12.60   -7.36%
11/08/18 175.99 183.67 164.00 1,572,913 171.19 8.21   5.04%
11/07/18 161.56 165.59 160.10 841,164 162.98 3.00   1.88%
11/06/18 159.20 162.14 157.20 840,896 159.98 0.65   0.41%
11/05/18 165.74 169.83 159.29 4,903,928 159.33 -6.39   -3.86%
Download Data To Spreadsheet
Ligand Pharm (LGND) Stock Rating from Louis Navellier

Navellier Ratings

Powered by Portfolio Grader

Ligand Pharm Stock Analysis

Rating: Buy

Total Grade: B

Analysis Breakdown

LGND Stock Grade: B
Fundamental Grade: B
Quantitative Grade: B
LGND Earnings
Earnings Growth: A
Earnings Momentum: D
Earnings Surprises: A
Analyst Earnings Revisions: A
LGND Financial Information
Sales Growth: A
Operating Margin Growth: A
Cash Flow: B
Return on Equity: A

Ligand Pharm Stock: Weekly View

This Week: B
Last Week: B
Two Weeks Ago: B
Get Full Report